Home › Head and Neck Squamous Cell Carcinoma › Kentucky
Head and Neck Squamous Cell Carcinoma clinical trials in Kentucky
17 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in Kentucky.
Cities in Kentucky
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- University of Kentucky/Markey Cancer Center, Lexington
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Nov 12, 2026 · NCT04671667Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Norton Cancer Institute, Louisville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- University of Kentucky Medical Center, Lexington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- University of Kentucky Markey Cancer Center, Lexington
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Nov 3, 2026 · NCT04892173FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- University of Kentucky, Markey Cancer Center (Site # 109), Lexington
- Norton Cancer Institute (Site#0111), Louisville
- The University of Louisville, James Graham Brown Cancer Center (Site#0115), Louisville
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06788990Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
- University of Kentucky/Markey Cancer Center, Lexington
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07156227Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
- Norton Cancer Institute, Louisville
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06295731A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- St. Elizabeth Healthcare, Edgewood
- Norton Cancer Institute, Louisville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06769698A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 115, Louisville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT05914116A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- University of Louisville Health, Louisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07768189Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Norton Cancer Institute, Louisville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- CommonSpirit Saint Joseph Hospital - Lexington, Lexington
- and 6 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- University of Kentucky/Markey Cancer Center, Lexington
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04333537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Baptist Health Hardin, Elizabethtown
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Norton Cancer Institute /ID# 248903, Louisville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05005403A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Lexington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT06256588A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- University of Kentucky Markey Cancer Center, Lexington
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.